Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PDUFA Negotiations Begin With FDA Seeking Review System Reform

This article was originally published in The Pink Sheet Daily

Executive Summary

Fee structure changes and process enhancements floated during opening session between industry and agency.

You may also be interested in...



FDA Safety Reports: Firms Want Advance Notice Before Public Release

PDUFA renewal could establish process that allows firms early warnings about Sentinel and other safety data announcements.

FDA's Ongoing User Fee System Upgrade Limits Payment Options

But it comes at a time when there is traditionally a lull in filings of generic drug applications.

PDUFA VI: FDA Wary Of Industry Proposals With More Metrics

Review system proposals could overburden staff, FDA says; formal meeting goals already on tap for changes.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS077872

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel